Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.40
Nov 20 • 10:31 AM ET Dollar change+0.01 Percentage change(0.13%)
Index
RUT
Market Cap
223.81M
Enterprise Value
-20.54M
Income
-61.73M
Sales
40.76M
Book/sh
14.07
Cash/sh
13.22
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
78
IPO
Apr 08, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
5.49
P/B
0.81
P/C
0.86
P/FCF
-
EV/EBITDA
-
EV/Sales
-0.50
Quick Ratio
18.14
Current Ratio
18.14
Debt/Eq
0.05
LT Debt/Eq
0.04
Option/Short
Yes / Yes
EPS (ttm)
-2.82
EPS next Y
-5.28
EPS next Q
-1.56
EPS this Y
-258.28%
EPS next Y
-45.00%
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-277.31%
Sales Y/Y TTM
-83.48%
EPS Q/Q
488.28%
Sales Q/Q
180.53%
Insider Own
8.45%
Insider Trans
-0.98%
Inst Own
93.75%
Inst Trans
-5.11%
ROA
-11.76%
ROE
-12.56%
ROIC
-21.17%
Gross Margin
96.10%
Oper. Margin
-179.54%
Profit Margin
-151.43%
SMA20
7.32%
SMA50
3.31%
SMA200
-0.45%
Trades
Shs Outstand
19.83M
Shs Float
17.97M
52W High
22.55 -49.42%
52W Low
8.98 27.00%
Volatility
10.78% 7.39%
ATR (14)
0.76
RSI (14)
56.65
Beta
1.13
Rel Volume
1.21
Avg Volume
195.78K
Volume
46,912
Perf Week
10.73%
Perf Month
0.48%
Perf Quarter
5.80%
Perf Half Y
1.92%
Perf YTD
-43.98%
Perf Year
-32.19%
Perf 3Y
-61.98%
Perf 5Y
-80.94%
Perf 10Y
-
Prev Close
11.39
Price
11.40
Change %
0.13%
Consensus
Buy
Avg. Price Target
$20.00
Implied Upside
+75.4%
Analysts13incl. previous ratings
Rating Distribution6 Buy · 7 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 20, 2025Initiated
WFC logoWWells Fargo
Overweight$26+128.0%
Jun 10, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$18+57.8%
Jan 21, 2025Downgrade
CCantor Fitzgerald
Overweight → Neutral
Jan 17, 2025Downgrade
WWedbush
Outperform → Neutral$15+31.5%
Dec 16, 2024Reiterated
OPY logoOOppenheimer
Outperform$102 → $63+452.4%
Dec 16, 2024Downgrade
GGuggenheim
Buy → Neutral
Dec 13, 2024Reiterated
HH.C. Wainwright
Buy$100 → $47+312.1%
Dec 12, 2024Downgrade
WWilliam Blair
Outperform → Mkt Perform
Dec 12, 2024Downgrade
TD logoTTD Cowen
Buy → Hold
Dec 12, 2024Downgrade
BBTIG Research
Buy → Neutral
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Newton Charles W.DirectorNov 17 '26Sale10.855515,98111,563Nov 19 04:10 PM
Prener AnneDirectorNov 17 '26Sale10.835756,23012,637Nov 19 04:10 PM
Newton Charles W.DirectorNov 17 '26Proposed Sale10.025515,521Nov 17 04:07 PM
Prener AnneDirectorNov 17 '26Proposed Sale10.025755,762Nov 17 04:06 PM
Prener AnneDirectorNov 12 '26Proposed Sale9.795745,619Nov 12 04:02 PM
Tanini AnnitaCorp. Controller & VP, FinanceAug 18 '26Sale10.291,22412,59545,144Aug 20 04:10 PM
Lerner Lorena RaquelChief Scientific OfficerAug 18 '26Sale10.293,56836,71527,559Aug 20 04:10 PM
Cho EstherChief Legal OfficerAug 18 '26Sale10.294,48546,15135,770Aug 20 04:10 PM
Newton Charles W.DirectorAug 18 '26Sale10.305515,67512,114Aug 20 04:10 PM
BIENAIME JEAN JACQUESDirectorAug 17 '26Buy10.271,00010,27019,592Aug 19 04:10 PM
Newton Charles W.DirectorAug 18 '26Proposed Sale10.385515,719Aug 18 04:11 PM
BIENAIME JEAN JACQUESDirectorJul 15 '26Buy10.611,00010,61018,592Jul 17 04:10 PM
BIENAIME JEAN JACQUESDirectorJun 15 '26Buy10.191,00010,19017,592Jun 17 04:55 PM
Newton Charles W.DirectorJun 11 '26Sale10.045505,52212,665Jun 15 04:15 PM
Newton Charles W.DirectorJun 11 '26Proposed Sale9.955505,472Jun 11 04:15 PM
Farzan NimaDirectorJun 04 '26Sale10.732,62528,1669,767Jun 08 04:37 PM
Knowles JuliusDirectorJun 04 '26Sale10.732,62528,16610,958Jun 08 04:36 PM
Seth AlpnaDirectorJun 04 '26Sale10.722,62528,1409,767Jun 05 04:15 PM
Farzan NimaDirectorJun 04 '26Proposed Sale10.682,62528,035Jun 04 04:11 PM
Knowles JuliusDirectorJun 04 '26Proposed Sale10.682,62528,035Jun 04 04:09 PM
Seth AlpnaDirectorJun 04 '26Proposed Sale10.682,62528,035Jun 04 04:07 PM
BIENAIME JEAN JACQUESDirectorMay 15 '26Buy10.581,00010,5809,450May 19 04:15 PM
BIENAIME JEAN JACQUESDirectorApr 15 '26Buy11.701,00011,7008,450Apr 17 04:15 PM
Seehra JasbirCHIEF EXECUTIVE OFFICERApr 02 '26Option Exercise0.3055,00016,500440,708Apr 06 04:15 PM
OrbiMed Genesis Master Fund, LShareholderMar 31 '26Proposed Sale11.0445,057497,429Mar 31 09:57 PM
BIENAIME JEAN JACQUESDirectorMar 09 '26Buy11.212,00022,4207,450Mar 11 04:33 PM
Seehra JasbirCHIEF EXECUTIVE OFFICERFeb 19 '26Sale16.177,015113,433385,708Feb 20 04:15 PM
Lerner Lorena RaquelChief Science OfficerFeb 18 '26Sale16.353,87363,32431,127Feb 20 04:15 PM
Cho EstherSVP, General CounselFeb 18 '26Sale16.354,74577,58139,755Feb 20 04:15 PM
Regnante KeithCHIEF FINANCIAL OFFICERFeb 18 '26Sale16.354,73977,48339,261Feb 20 04:15 PM
Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.
PresidentDr. Jasbir S. Seehra Ph.D.
Chief Legal Officer & SecretaryMs. Esther Cho J.D.
VP of FinanceMs. Annita Tanini
Head of Investor RelationsJustin Frantz
Chief Scientific OfficerDr. Lorena Lerner Ph.D.